Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 4043 (117th)

Ensuring Patient Access to Critical Breakthrough Products Act of 2021

referredUnited States· United States Congress· EN

Introduced

22 June 2021

Last action

23 June 2021 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. DelBene, Suzan K. [D-WA-1], Rep. Walorski, Jackie [R-IN-2], Rep. Cárdenas, Tony [D-CA-29], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Sewell, Terri A. [D-AL-7], Rep. Upton, Fred [R-MI-6], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Houlahan, Chrissy [D-PA-6], Rep. Dunn, Neal P. [R-FL-2], Rep. Bera, Ami [D-CA-6], Rep. McGovern, James P. [D-MA-2], Rep. Boyle, Brendan F. [D-PA-2], Rep. Correa, J. Luis [D-CA-46], Rep. Wenstrup, Brad R. [R-OH-2], Rep. Crenshaw, Dan [R-TX-2], Rep. Schrier, Kim [D-WA-8], Rep. Wild, Susan [D-PA-7], Rep. Pappas, Chris [D-NH-1], Rep. Peters, Scott H. [D-CA-50], Rep. Craig, Angie [D-MN-2], Rep. McKinley, David B. [R-WV-1], Rep. Kelly, Mike [R-PA-16], Rep. Lieu, Ted [D-CA-36], Rep. Aguilar, Pete [D-CA-33], Rep. Cheney, Liz [R-WY-At Large], Rep. Emmer, Tom [R-MN-6], Rep. Miller, Carol D. [R-WV-1], Rep. Steel, Michelle [R-CA-48], Rep. Dean, Madeleine [D-PA-4], Rep. Smucker, Lloyd [R-PA-11], Rep. Joyce, John [R-PA-13], Rep. Smith, Jason [R-MO-8], Rep. Lamb, Conor [D-PA-17], Rep. Auchincloss, Jake [D-MA-4]

Subjects

Healthcare

Source updated

3 January 2025

Healthcare

Summary

Ensuring Patient Access to Critical Breakthrough Products Act of 2021 This bill provides for Medicare coverage of medical devices that are approved under the Food and Drug Administration (FDA) Breakthrough Devices Program. (Under the program, manufacturers work with the FDA to expedite the review and approval of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions.) The bill allows designated medical breakthrough devices to be temporarily covered under Medicare during a four-year transitional period. The Centers for Medicare & Medicaid Services (CMS) must assign payment codes for such devices within three months of FDA approval. The CMS must also establish a process to allow for continued coverage after the transitional period has expired, taking into account any additional evidence or data the CMS deems necessary. The CMS must also provide for temporary and, where appropriate, permanent Medicare coverage of breakthrough devices for which there is no existing benefit category (i.e., classification).

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 22 June 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  2. 22 June 2021

    Introduced

    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 22 June 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 22 June 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 23 June 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 22 June 2021

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 22 June 2021

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 22 June 2021

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.